Investigating infections caused by antibiotic-resistant enterococci
Official title: VENOUS: A translational study of enterococcal bacteremia
Funded at Methodist Hospital Research Institute · NIH-10849696 · Data updated 2026-11-12
This study is looking at how infections from hard-to-treat bacteria called vancomycin-resistant enterococci (VRE) affect people with weakened immune systems or other health problems, and it aims to find better ways to treat these infections to help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 17, 2020 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $747,390 |
| NIH project number | 5R01AI148342-05 |
| Project ID | NIH-10849696 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include immunocompromised individuals, such as those with hematological malignancies or solid organ transplant recipients, who are at high risk for VRE infections.
✕Less likely to help
Patients who do not have significant comorbidities or are not immunocompromised may not benefit from this research.
What this research studies
This research focuses on enterococcal bacteremia, particularly in patients with weakened immune systems or multiple health issues. It aims to understand the clinical impact of infections caused by vancomycin-resistant enterococci (VRE), which are difficult to treat due to their resistance to many antibiotics. The study will involve collecting clinical data to guide treatment options and improve outcomes for affected patients. By examining the effectiveness of existing antibiotics and exploring new treatment strategies, the research seeks to address a significant gap in managing these serious infections.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols for patients suffering from severe infections caused by antibiotic-resistant enterococci.
How similar studies have gone: While there is limited research specifically on VRE infections, studies on antibiotic-resistant bacteria have shown promise in improving treatment outcomes through targeted approaches.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Arias, Cesar Augusto — Methodist Hospital Research Institute
- Study coordinator: Arias, Cesar Augusto
Related research
Other NIH-funded projects on the same topics.
-
Collaborative AI for safer, faster bacteremia care
A physician-centered AI system is being built to help diagnose and treat bloodstream infections more accurately and safely, with the goal of reducing sepsis deaths.
-
Rapid pathogen ID and antibiotic testing for bacteremia using immune capture, microfluidics, and AI
A fast, AI-assisted diagnostic system will identify bacteria in blood and determine which antibiotics are likely to work, helping doctors treat bacteremia sooner.
-
Predicting which febrile kids with sickle cell disease are at low risk for bacteremia
A small, patient-facing prediction rule is being developed to help doctors decide which febrile children with sickle cell disease really need aggressive testing and antibiotics.
-
Multimodal antibody therapy to treat Staphylococcus aureus bloodstream infections
A hospital-focused immunotherapy approach uses a mix of antibodies to help fight blood infections from Staphylococcus aureus by blocking immune evasion and bacterial growth.
-
Defining how macrophages fight Klebsiella in the blood
This grant studies how innate immune cells called macrophages protect against Klebsiella pneumoniae bloodstream infections to help reduce sepsis mortality.
-
Epigenomic clues and immune context in stubborn MRSA bloodstream infections
Researchers are studying why some MRSA bloodstream infections persist despite antibiotics and how the immune system and bacterial DNA packaging (epigenetics) influence this, with the goal of better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.